4,5,15,22-26 pointed to human TRIM5α being the CypA-sensitive restriction factor. However, HIV-1 restriction by human TRIM5α in tumour cell lines is minimal 21 and inhibition of such activity by CypA has not been detected 27 . Here, by exploiting reverse genetic tools optimized for primary human blood cells, we demonstrate that disruption of the CA−CypA interaction renders HIV-1 susceptible to potent restriction by human TRIM5α, with the block occurring before reverse transcription. Endogenous TRIM5α associated with virion cores as they entered the cytoplasm, but only when the CA−CypA interaction was disrupted. These experiments resolve the long-standing mystery of the role of CypA in HIV-1 replication by demonstrating that this ubiquitous cellular protein shields HIV-1 from previously inapparent restriction by human TRIM5α.
macrophages, dendritic cells or CD4 + T cells ( Fig. 1a-d ; Extended Data Fig. 3a ). The infectivity of HIV-1 CA-P90A, a mutant that disrupts CypA binding 8, 9 , was attenuated compared to the WT in control knockdown cells generated with all three cell types ( Fig. 1a-d) .
The effect was evident in cells from all blood donors tested (at least three blood donors per condition) and over a 100-fold range in challenge vector titre (Extended Data Fig. 3a ). TRIM5 knockdown in macrophages, dendritic cells or CD4 + T cells increased CA-P90A infectivity ( Fig. 1a-d ; Extended Data Fig. 3a ). Results were the same whether the challenge was with a three-plasmid vector system based on the clade B HIV-1 NL4-3 lab strain 30, 32 (Fig. 1a-c) or a two-plasmid vector system based on the clade C HIV-1 ZM249M transmissionfounder strain from Zambia 30, 33 (Fig. 1d) .
Given previous reports that endogenous human TRIM5α in immortalized cell lines has a modest effect on HIV-1 infectivity, and that CypA and TRIM5α act independently to regulate HIV-1 transduction 27 , the relatively large magnitude rescue of CA-P90A infectivity by TRIM5 knockdown in primary human blood cells was surprising. Complementary pharmacologic and reverse genetic approaches were therefore used to disrupt the CA−CypA interaction. For pharmacologic disruption, cells were incubated in media containing small molecules that compete with CA for binding to CypA 2, [8] [9] [10] 34 . Compared to dimethylsulfoxide (DMSO) solvent alone, cyclosporine A (CsA) reduced HIV-1 transduction efficiency in Luc control knockdown macrophages (Fig. 1e ). In contrast, cyclosporine H (CsH), an analogue with 1,000-fold lower affinity for CypA 35 , caused only a slight increase in HIV-1 infection (Extended Data Fig. 3b ). Since CsA blocks T cell proliferation, two non-immunosuppressive CypA inhibitors derived from sanglifehrin A, GS−CypAi3 and GS−CypAi48 (ref. 34 ), were used instead on this cell type; these drugs decreased HIV-1 transduction efficiency in primary CD4 + T cells ( Fig. 1f ; Extended Data Fig. 3c-e ). TRIM5 knockdown reversed the HIV-1 inhibition in macrophages caused by CsA (Fig. 1e ), or in CD4 + T cells caused by the sanglifehrin A-derivatives ( Fig. 1f ; Extended Data Fig. 3c-e ).
To disrupt the CA−CypA interaction using a genetic approach, macrophages were transduced with two vectors for the knockdown of either TRIM5 or CypA, or both. The first vector conferred puromycin resistance and expressed shRNAs targeting either TRIM5 or Luc. The second vector conferred blasticidin resistance and expressed shRNAs targeting either CypA or Luc. After simultaneous transduction with pairs of these vectors, macrophages were selected for three days in both puromycin and blasticidin and then Letters NATuRE MICRobIoloGy challenged with single-cycle, VSV G-pseudotyped, HIV-1−GFP reporter vector bearing WT CA. Compared to the Luc control knockdown, CypA knockdown reduced CypA protein levels ~70% (Extended Data Fig. 2d ). As with CA-P90A and the small molecule inhibitors, CypA knockdown decreased transduction efficiency (Fig. 1g ). This effect was rescued by simultaneous knockdown of TRIM5 ( Fig. 1g ) without restoring CypA protein levels (Extended Data Fig. 2d ). Taken together, these data indicate that endogenous human TRIM5 is required for HIV-1 restriction in the absence of the CA−CypA interaction. Consistent with the previously reported CA-specific saturation of TRIM5 restriction activity 13, 27 , the effective titre of HIV-1−GFP reporter vector bearing CA-P90A was increased in a dose-dependent manner by the addition of virus-like particles (VLPs) bearing CA-P90A, but not by VLPs bearing WT CA (Extended Data Fig. 4 ).
Although the shRNA that targets TRIM5 is distinguished from the next most similar sequence in the human genome (GRCh38) by multiple mismatches, off-target effects are theoretically possible. To test whether TRIM5α is sufficient to explain the HIV-1 restriction activity associated with CA−CypA disruption, a vector was designed based on the ubiquitin fusion technique 36 that expresses a tripartite fusion of puromycin N-acetyl transferase (Puro R ), the K48R mutant of ubiquitin (Ub K48R ) and the coding sequence for a protein of interest, in addition to an shRNA ( Fig. 2a ). Four variants of the plasmid were engineered in which the shRNA targeted either TRIM5 or Luc, with or without a TRIM5α coding sequence bearing mismatches in the shRNA target sequence ( Fig. 2a ).
Macrophages (Fig. 2b ) and CD4 + T cells ( Fig. 2c ) were transduced with each of the four variants of the shRNA tripartite fusion vector and selected for three days with puromycin. Cells were then challenged with the three-plasmid HIV-1−GFP reporter vector used in Fig. 1a -c and assessed by flow cytometry for percentage of GFP + cells three days later. As in Fig. 1 , the infectivity of the vector bearing WT CA was minimally affected by TRIM5 knockdown or by TRIM5α overexpression (Fig. 2b,c ). Compared to the WT, the infectivity of vector bearing CA-P90A was decreased ( Fig. 2b,c ) and the infectivity of this mutant was rescued by TRIM5 shRNA (Fig. 2b,c) . In the presence of shRNA targeting TRIM5, delivery of Relative infectivity (%) P = 0.0079 10.4× P = 0.00005 25.4× P = 0.0322 3.8× P = 0.0005 4.8× P = 0.0244 3.4× P = 0.0011 6.3× P = 0.0094 6.2× P = 0.00001 9.3× P = 0.0331 5.6× P = 0.0005 9.5× P = 0.0402 5.1× P = 0.0011 10.5× P = 0.0369 6.8× P = 0.0007 6.9× donors for each). e, TrIM5 knockdown or Luc knockdown macrophages were challenged with HIV-1 NL4-3 −GFP in the presence of 8 µM CsA or DMSO solvent (mean ± s.e.m., n = 4 donors). f, TrIM5 knockdown or Luc knockdown CD4 + T cells were challenged with HIV-1 ZM249M −GFP in the presence of 2.5 µM GS−CypAi3 or DMSO solvent (mean ± s.e.m., n = 3 donors). g, Macrophages were transduced simultaneously with two vectors expressing shrNAs, as indicated, and selected with puromycin and blasticidin. Cells were then challenged with HIV-1 NL4-3 −GFP (mean ± s.e.m., n = 3 donors). The percentage of GFP + cells was assessed by flow cytometry and normalized to the WT in Luc control knockdown cells in all cases. Significance was determined by two-tailed, paired Student's t-test.
DMSO

Letters
NATuRE MICRobIoloGy
TRIM5α coding sequence bearing shRNA target-site mismatches restored restriction activity to the control level ( Fig. 2b,c) . These results demonstrate that, in primary human blood cells, human TRIM5α is sufficient to restrict HIV-1 transduction, but only when the CA−CypA interaction is disrupted.
To determine at which step in the virus life cycle human TRIM5α inhibits HIV-1 when the CA−CypA interaction is disrupted, HIV-1 complementary DNA (cDNA) resulting from reverse transcription was assessed by qPCR. Macrophages and CD4 + T cells were stably transduced and selected with vector expressing shRNAs targeting TRIM5 or Luc (control) ( Fig. 2d,e ), or with each of the four variants of the shRNA tripartite fusion vector ( Fig. 2f ,g). Cells were then challenged with a HIV-1 reporter vector that had the 34 base pair loxP sequence in the U3 region of the 3' long terminal repeat to distinguish reporter vector transcripts from those of the shRNA lentivector 37 . DNA was collected 20 h post challenge and qPCR was performed using primers specific for full-length linear HIV-1 cDNA (late RT). In all experiments, reporter vector bearing the RT-D185K/D186L loss-of-function mutation 37 was included as a control for background signal not due to nascent reverse transcription ( Fig. 2d -g). , macrophages (f) or CD4 + T cells (g) transduced with the all-in-one shrNA-rescue lentivectors described in a were challenged with HIV-1 NL4-3 −GFP containing WT CA or CA-P90A, as indicated. DNA was extracted 20 h post challenge and late products of reverse transcription were assessed by qPCr (mean ± s.e.m., n = 3 biologically independent samples). rT-D185K/D186L mutant virus was used as a control for background signal. Significance was determined by two-tailed, unpaired Student's t-test.
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In Luc control knockdown macrophages and CD4 + T cells, viral cDNA was reduced by CA-P90A and this reduction was reversed by TRIM5 knockdown (Fig. 2d,e ). Viral cDNA was also reduced by CA-P90A in either cell type transduced with the control shRNA tripartite fusion vector ( Fig. 2f ,g). TRIM5 shRNA rescued the cDNA ( Fig. 2d -g) and rescue of TRIM5α with the non-targetable coding sequence again decreased the CA-P90A cDNA ( Fig. 2f,g) . These results demonstrate that, when the CA−CypA interaction is disrupted, human TRIM5α blocks HIV-1 at an early step of viral infection, before the completion of reverse transcription.
To determine whether TRIM5α associates with HIV-1 CA in cells when the CA−CypA interaction is disrupted, primary human macrophages were stably transduced with TRIM5 shRNA or Luc shRNA and then challenged for 2 h with WT HIV-1 reporter vector in the presence or absence of CsA, or with HIV-1 vectors bearing WT CA or CA-P90A. Cells were fixed and subjected to the proximity ligation assay (PLA) with antibodies specific for HIV-1 CA and endogenous human TRIM5α. When cells were challenged with WT HIV-1 in the absence of CsA, very few punctae were detected ( 
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this indicated that the PLA signal was dependent on TRIM5 expression. The PLA signal was also dependent on the proteasome inhibitor MG132 (Extended Data Fig. 6 ), a result consistent with the reported involvement of the proteasome in the inhibition of reverse transcription by TRIM5α 38 . These results indicate that, in the infection of primary human cells, endogenous TRIM5α associates with HIV-1 CA when the CA−CypA interaction is disrupted.
The above experiments used single-cycle HIV-1 vectors. The effect of CypA on HIV-1 restriction by human TRIM5α was therefore evaluated next using replication-competent HIV-1 in a context where the virus spreads from cell to cell. Primary human macrophages were challenged with clade B HIV-1 bearing a macrophagetropic env (HIV-1 MAC ) and replication was monitored for 14 days by measuring the accumulation of reverse transcriptase activity in the supernatant. As in the single-cycle experiments ( Fig. 1 ), TRIM5 knockdown itself had little effect on WT HIV-1 replication (Fig. 4a,b ). Disruption of the CA−CypA interaction with CsA ( Fig. 4a ) or with shRNA targeting CypA (Fig. 4b ) effectively suppressed viral spread in the culture and, in both cases, replication kinetics were completely restored to the control level by shRNA targeting TRIM5 (Fig. 4a,b ). Primary CD4 + T cells were then challenged with a clade C transmission-founder virus (HIV-1 ZM249M ). As observed in macrophages, TRIM5 knockdown alone had minimal effect on WT HIV-1 replication (Fig. 4c,d) . No viral replication was detectable when the CA−CypA interaction was disrupted by the small molecule GS−CypAi3 (Fig. 4c ) or by the presence of CA-P90A in HIV-1 (Fig. 4d ); in both cases shRNA targeting TRIM5 rescued replication kinetics to the level of the controls (Fig. 4c,d ). Furthermore, the shRNA tripartite fusion vectors were exploited to rule out offtarget effects of the shRNA and to demonstrate that TRIM5α is sufficient to restrict HIV-1 replication under conditions in which the CA−CypA interaction is interrupted (Fig. 4e) .
The experiments presented here demonstrate that, in primary human blood cells, HIV-1 exploits CypA to evade CA recognition by, and the antiviral activity of, endogenous TRIM5α. The simplest model is that CypA sterically blocks TRIM5α from binding to CA. Alternatively, since CypA possesses peptidyl-prolyl isomerase activity 39 and HIV-1 CA-P90 is a validated substrate 40 , CypA might shift the CA conformation and thereby protect HIV-1 CA from recognition by TRIM5α. This answers the long-standing question of how CypA promotes HIV-1 infection and clearly establishes that, in the absence of CypA, human TRIM5α potently restricts HIV-1. Conservation of the lentiviral CA−CypA interaction across millions of years of evolution is probably a result of selective pressure applied by TRIM5 orthologues encoded by host species that are otherwise permissive for lentiviral replication. In contrast to the results here, the observation that CypA promotes restriction in non-human primate cells [13] [14] [15] probably reflects a different mode of CA recognition by TRIM5α orthologues from these species. Finally, the results here indicate that, by rendering HIV-1 susceptible to the potent antiviral activity of TRIM5α, non-immunosuppressive CypA inhibitors have the potential to make an important contribution to anti-HIV-1 drug cocktails.
Methods
Plasmids. All the plasmids used here are described in Supplementary Table 1 Transduction with lentiviral knockdown vectors. For dendritic cells, 2 × 10 6 CD14 + monocytes ml −1 were transduced with a 1:4 volume of SIV−VLPs and a 1:4 volume of knockdown lentivector. For macrophages, 10 6 CD14 + monocytes ml −1 were transduced with a 1:8 volume of SIV−VLPs and a 1:8 volume of knockdown lentivector. The Vpx-containing SIV−VLPs were added to these cultures to overcome a SAMHD1 block to lentiviral transduction 42, 43 . Transduced cells were selected with 3 µg ml −1 puromycin (InvivoGen, catalogue no. ant-pr-1), 10 µg ml −1 blasticidin (InvivoGen, catalogue no. ant-bl-1) or both, for 3 d, starting 3 d post transduction.
Following isolation with magnetic beads, human CD4 + T cells were cultured at 2 to 3 × 10 6 cells ml −1 in RPMI−FBS complete, supplemented with 50 U ml −1 hIL-2 and stimulated with 5 µg ml −1 PHA-P (Sigma-Aldrich, catalogue no. L-1668). Alternatively, CD4 + T cells at 10 6 cells ml −1 were stimulated with 25 µl ml −1 ImmunoCult Human CD3/CD28 T Cell Activator (STEMCELL Technologies, catalogue no. 10991). At day 3 post stimulation, T cells were replated at 2 to 3 × 10 6 cells ml −1 in RPMI−FBS complete, with 50 U ml −1 hIL-2. Cells were transduced with 10 8 reverse transcription units (RTUs) of viral vector per 10 6 cells for 3 d, followed by selection with 2 µg ml −1 puromycin. After selection for 3 d, cells were restimulated with PHA-P or ImmunoCult Human CD3/CD28 T Cell Activator for 3 d. The stimulated cells were then replated at 2 to 3 × 10 6 cells ml −1 (PHA) or at 10 6 cells ml −1 (CD3/CD28) in RPMI−FBS complete with 50 U ml −1 hIL-2 and challenged with lentiviral vectors for the assessment of single-cycle infectivity or with replication competent HIV-1 for spreading infection. Fresh media containing hIL-2 was replenished every 2−3 d.
Infectivity assay using single-cycle viruses.
For human dendritic cells, 2.5 × 10 5 cells were seeded per well, in a 48-well plate, on the day of virus challenge. Media containing VSV G-pseudotyped lentiviral vector expressing GFP (HIV-1−GFP) was added to challenge cells in a total volume of 250 µl. For human macrophages, 2.5 × 10 5 cells were seeded per well in a 24-well plate and challenged with HIV-1− GFP in a total volume of 500 µl. The cells were also simultaneously challenged with HIV-1 VLPs, as indicated. A 1:50 volume of SIV−VLPs was also added to the medium during the virus challenge of dendritic cells or macrophages. To challenge human CD4 + cells activated with PHA, 5 × 10 5 cells were plated per well in a 96well plate 3 d after the second PHA stimulation. For CD4 + cells stimulated with CD3/CD28 activator, 2 × 10 5 cells were plated in each well of a 96-well plate, 3 d after secondary stimulation. Cells were then challenged with GFP reporter viruses in a total volume of 200 µl. For all three cell types, four dilutions of viral stocks, from 10 5 to 10 8 RTU ml −1 , were used to challenge cells. Where indicated, cells were pretreated with 8 µM CsA, 8 µM CsH or 2.5 µM of non-immunosuppressive CypA inhibitors from Gilead (GS−CypAi3 or GS−CypAi48) 34 , for 1 h before virus challenge. In experiments using CsH treatment, the media was replaced after 16 h of treatment to avoid CsH toxicity 44 .
At 48 h post challenge with two-part HIV-1 vectors, or at 72 h post challenge with three-part lentiviral vectors, cells were harvested for flow cytometric analysis by pipetting (CD4 + T cells) or scraping (dendritic cells and macrophages). Cells were pelleted at 500g for 5 min and fixed in a 1:4 dilution of BD Cytofix Fixation Buffer with phosphate-buffered saline (PBS) without Ca 2+ and Mg 2+ , supplemented with 2% FBS and 0.1% NaN 3 .
Flow cytometry. Data were collected on an Accuri C6 (BD Biosciences) and plotted with FlowJo software v.10. Infectivity at each dilution, in each condition (CA mutant, CypA inhibitor or CypA knockdown) was compared to the infectivity of WT CA in the control condition. Dilutions yielding infectivity greater than 30% GFP + cells were excluded from the analysis on the assumption that these were out of the linear range, according to the Poisson distribution.
Statistical analysis.
Experimental n values and information regarding the statistical tests can be found in the figure legends. The data for infectivity assays using single-cycle viruses including at least three independent donors were statistically analysed using two-tailed paired t-tests compared to the control condition or the indicated condition for each donor. The qPCR data for experiments measuring viral cDNA levels with three biologically independent samples for each condition were analysed using two-tailed, unpaired t-tests for the comparison of two conditions as indicated in Fig. 2 . The data from PLA quantification were assessed for statistical significance using two-tailed unpaired t-tests to compare two conditions as indicated in Fig. 4 . All statistical analyses were performed using PRISM 8.2 (GraphPad Software).
qPCR for viral late reverse transcriptase product. Total DNA was extracted from cells using DNeasy Blood & Tissue Kit (Qiagen), following the manufacturer's instructions. Late reverse transcription products were detected with the TaqMan system using the primers pWPTS J1B fwd and pWPTS J2 rev with the late reverse transcription probe (LRT-P) 45 . Mitochondrial DNA was used for normalization with the following primer/probe set: MH533, MH534 and Mito probe 46 . The . At 3 days post-transduction, cells were selected with puromycin for 3 days. Total rNA was isolated from the macrophages and dendritic cells, followed by cDNA synthesis, and qPCr with TaqMan detection of TrIM5 and the housekeeping gene OAZ1, for normalization (mean ± SeM, n = 3 independent samples). Significance was determined by two-tailed, unpaired t-test (a and b). The selected CD4 + T cells were challenged with N-or B-MLV vector harboring GFP reporter for 3 days. Flow cytometry was used to assess the percentage of GFP + cells. The infectivity of each vector in TrIM5 knockdown cells was normalized to the Luc control condition. Shown is mean ± SD (n = 3 donors for each). Significance was determined by two-tailed, paired t-test (c). d. Macrophages were simultaneously transduced with two lentiviral vectors, the first expressing shrNA targeting TrIM5 or Luc with Puro r , and the second expressing shrNA targeting CypA or Luc with blasticidin S-deaminase. After selection with both antibiotics, CypA and β-actin proteins were detected by western blot. Data shown is representative of three independent experiments using cells from three blood donors. Last updated by author(s): Sep 11, 2019 Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
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Sample size
Pre-experiment, sample-size calculation was not performed, since effect size was unknown. In each case, experiments were performed using cells from at least three independent blood donors. The effects in our experiments were in fact large and reproducible, thus sample size calculation was not required.
Data exclusions No data was excluded from analysis.
Replication
All experiments were performed with three technical replicates on at least three blood donors (biological replicates). Successful replication was confirmed.
Randomization Randomization is not customary for standard molecular biology experiments such as these.
Blinding
For most experiments, investigators were not blinded to group allocation during data collection and analyses, since the results produce hard numbers with little need for interpretation. The outcomes in our experiments were clear, reproducible, and large in effect. The exception was the PLA assays, where the investigator who ran the microscopy software was blinded to the identity of the samples.
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Materials
Validation
All antibodies used in this study were validated by manufacturers and published papers. Anti-CD14 antibody microbeads and anti-CD4 antibody microbeads used for cell isolation by positive selection were validated by checking the surface markers of the isolated cells. FITC-anti-CD3 and APC-anti-CD4 were validated by staining the surface markers of cells having CD3 and CD4, or none, along with isotype control antibodies. Anti-Cyclophilin A was shown specific in our experiment by checking the protein expression in comparison to knockdown cells (Extended Data Fig. 2d ). Anti-TRIM5alpha and Anti-p24 were also shown specific in our PLA imaging experiment by observing the fluorescent signals in comparison to knockdown cells or to cells without virus challenge ( Fig. 3 ; Extended Data Fig. 5 and 6 ).
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Eukaryotic cell lines Policy information about cell lines
Cell line source(s) HEK293 cells were acquired from ATCC.
Authentication
No authentication was performed for HEK293 cells.
Mycoplasma contamination
HEK293 cells tested negative for mycoplasma contamination by us.
Commonly misidentified lines (See ICLAC register)
None of the commonly misidentified cell lines were used in this study.
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Methodology
Sample preparation
Cells were fixed with BD CytoFix Fixation buffer prior to data acquisition on BD Accuri C6.
Instrument BD Accuri C6
Software BD Accuri C6 software 1.0.264.21 for data collection; FlowJo10 software for data analysis Cell population abundance Cell surface markers were used to confirm enrichment of the CD4+ T cells, macrophages, and dendritic cells
Gating strategy
Gating strategy for flow cytometry data is presented in the Supplementary Information.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
